Abstract:Objective To investigate the treatment,outcomes and disease burden of severe hand-foot-and mouth diseases(HFMD),and to evaluate the compliance to the 2011 guideline for treatment in regions with a high in-cidence of HFMD.Methods A collaborative study group was established including Children's Hospital of Fudan Uni-versity,Jiangxi Provincial Children's Hospital,Anhui Provincial Children's Hospital,Linyi People's Hospital and the Second People's Hospital of Fuyang City.Clinical manifestation,treatment,prognosis and other data of severe HFMD pa-tients were prospectively collected by filling out a survey form in real time from April 2014 to October 2016. Results Two hundred and twenty-six severe HFMD cases were collected during the research time,including 114 ca-ses in stage 2,75 cases in stage 3,and 37 cases in stage 4.Two hundred and twenty-one cases(97.8%)were given mannitol,with a mortality of 6.2%;91 cases(40.3%)were given mannitol and glycerol fructose,with a mortality of 3.3%;the combined use of mannitol and glycerol fructose might have a better result than the single use of mannitol. One hundred and ninety-eight cases(87.6%)were given intravenous immunoglobulin(IVIG).One hundred and ninety cases(84.1%)were given antiviral drugs.One hundred and forty-five cases(64.2%)were given hormone therapy,and the use of hormone could reduce temperature,but did not reduce the mortality.One hundred and fifty cases (66.4%)needed vasoactive agent,including milrinone,dobutamine,phentolamine and sodium nitroprusside. The vasoactive agent use in stage 3 and 4 were 88.0%(66/75 cases)and 91.9%(34/37 cases),respectively.Sixty-nine cases(30.5%)received continuous positive airway pressure(CPAP),91 cases(40.3%)with mechanical ventila-tion,peak inspiratory pressure(PIP)≥20 cmH2O(1 cmH2O=0.098 kPa)accounted for 61.6%(53/86 cases),po-sitive end-expiratory pressure(PEEP)≥10 cmH2O accounted for 36.3%(33/91 cases).The mean mechanical ven-tilation time was(125.9 ± 101.8)h.Eleven cases(4.86%)died or died after giving up treatment,in which the mortality in stage 3 was 6.7%(5/75 cases),and the mortality in stage 4 was 16.2%(6/37 cases).The death causes were respiratory failure,pulmonary hemorrhage,and circulatory failure. The average time from onset to death was (5.91 ± 5.26)(1-15)d.Length of stay in hospital was(9.18 ± 5.16)(1-37)d in which length of stay in hospi-tal in stage 3 and 4 were(11.3 ± 6.35)d,(11.4 ± 6.62)d,respectively,which were significantly longer than that in stage 2[(7.50 ± 3.04)d],and the difference was statistically significant(P <0.05). The cost was(19 136 ± 12 556)CNY,of which the cost in stage 3 and 4 was(23 121 ± 13 846)CNY,(29 849 ± 16 015)CNY,respectively, which were significantly higher than that in stage 2[(12 961 ± 4 272)CNY],and the difference was statistically sig-nificant(P<0.05). Multivariate analysis found that respiratory rhythm abnormality,capillary refill time more than 3 seconds were risk factors for the deaths in the severe HFMD.Conclusion The 2011 edition of guidelines for treat-ment of children with severe HFMD was well executed.Hormone,IVIG,antiviral drugs did not significantly reduce the mortality of severe HFMD in children.

Diagnosis and Treatment of Neurogenic Pulmonary Edema in Children with Severe Hand, Foot and Mouth Disease

Acute neurogenic pulmonary edema caused by hand, foot and mouth disease: a case report

Analysis of the Treatment Response and Prognosis of Severe Hand-Foot-mouth Disease

Clinical features and emergency management of severe encephalitis and neurogenic pulmonary edema caused by enterovirus type 71 in children

Clinical Characteristics and Treatment of Severe Encephalitis Associated with Neurogenic Pulmonary Edema Caused by Enterovirus 71 in China.

Risk factors for neurogenic pulmonary edema in patients with severe hand, foot, and mouth disease: A meta-analysis

Dynamic Changes in Serum Inflammatory Cytokines and Their Association with Neurogenic Pulmonary Edema in Patients with Severe Hand-Foot-mouth Disease

Neurological complications and risk factors of cardiopulmonary failure of EV-A71-related hand, foot and mouth disease

The diagnosis and treatment in 2 patients with the fulminant pulmonary edema

Significance of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Levels in Evaluation of Severe Hand ,foot ,and Mouth Disease Complicated with Neurogenic Pulmonary Edema

[Risk Factors of Heart and Lung Failure in Children with Severe Hand, Foot and Mouth Disease and Treatment Experience].

The Influence of Blood Coagulation and Physiology Function of high Positive end Expiratory Pressure Indication of Mechanical Ventilation on Patients with Neurogenic Pulmonary Edema

Clinical Features of 80 Severe Cases of Hand-Foot-mouth Disease of Shenzhen in 2008

Multicenter Clinical Epidemiologic Study for Treatment of Severe Hand-Foot-and Mouth Disease

Clinical features for 89 deaths of hand, foot and mouth disease in Guangxi, China, 2014

Analysis of the clinical features, prognosis and early warning indicators of severe hand, foot and mouth disease

Clinical and laboratory features in 118 cases with severe hand-foot-mouth disease

Diagnosis and treatment of gastrointestinal dysfunction in children with severe enterovirus 71 infection

Neurogenic pulmonary edema following cerebrovascular diseases

Neuro-Magnetic Resonance Imaging in Hand, Foot, and Mouth Disease: Finding in 412 Patients and Prognostic Features.

A Multicenter Study on Clinical Characteristics of Severe Hand,foot and Mouth Disease in East China